Introduction {#sec1}
============

Autoimmune diseases are chronic disorders characterized by the loss of immune tolerance to self-antigens, leading to immune-mediated tissue destruction. They affect 4--5% of adults, the majority of whom are women \[[@B1]\]. Co-occurrence of distinct autoimmune diseases within a single family and genome-wide association studies (GWASs) support the hypothesis that these diseases share common genetic risk factors \[[@B2]\]. The etiology of autoimmune diseases is attributed to complex interactions of genetics, epigenetics, and environmental factors that remain to be elucidated \[[@B7]\].

FAS (also known as APO-1, CD95, or TNFSF6) is a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor superfamily \[[@B13]\]. FAS is widely expressed in normal human tissues. To maintain self-tolerance, the binding of FAS-ligand (FASL) to FAS on the cell surface initiates the extrinsic apoptosis pathway \[[@B14]\]; thus, autoreactive lymphocytes are normally eliminated. However, abnormal apoptosis may lead to a failure to eliminate autoreactive lymphocytes, which can induce the appearance and development of autoimmune diseases \[[@B15]\]. The *FAS* gene is located on chromosome 10q24.1 in humans and is highly polymorphic \[[@B16]\]. In some individuals, there is an A to G substitution at position 670 and a G to A substitution at position 1377 in the *FAS* promoter region \[[@B17]\]. The *FAS* −670 A/G and −1377 G/A polymorphisms may destroy signal transducer and activator of transcription protein 1 (STAT1) and stimulatory protein 1 (SP1) transcription factor binding sites, resulting in reduced promoter activity and *FAS* expression \[[@B18]\]. Abnormal apoptosis mediated by the FASL interaction with the FAS receptor is involved in the pathogenesis of several autoimmune diseases and cancers \[[@B19]\].

Many studies have investigated the relationship between the *FAS* −670 A/G rs1800682 and −1377 G/A rs2234767 polymorphisms and the risk of autoimmune diseases \[[@B15],[@B17],[@B20]\], including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), autoimmune hepatitis (AIH), alopecia areata (AA), lupus nephritis (LN), systemic sclerosis (SSc), primary Sjögren's syndrome (pSS), Hashimoto's thyroiditis (HT), Guillain--Barré syndrome (GBS), primary biliary cirrhosis (PBC), vitiligo, Graves' disease (GD), type 1 diabetes mellitus (T1D), idiopathic aplastic anemia (IAA), juvenile idiopathic arthritis (JIA), and spondyloarthropathies (SPA). However, previous results have been controversial, perhaps due to small sample sizes and low statistical power. Meta-analysis could provide more reliable results, enabling the inclusion of a larger sample size and enhanced statistical power by combining the results of independent eligible studies. Seven previous meta-analyses \[[@B43],[@B61]\] have analyzed the association between the *FAS* −670 A/G or −1377 G/A polymorphisms and some autoimmune diseases. However, these studies only analyzed SLE, RA, LN, SSc, pSS, JIA, SPA, and AIH and did not include all autoimmune diseases. Furthermore, previous meta-analyses \[[@B63],[@B65]\] including several studies \[[@B25],[@B30],[@B31],[@B40]\] contained some errors when extracting the data. Thus, in the present study, we aimed to perform a meta-analysis to investigate whether the *FAS* −670 A/G or −1377 G/A polymorphisms is associated with autoimmune diseases risk by including 23 new articles, consisting of 33 studies \[[@B15],[@B17],[@B22],[@B27],[@B32],[@B37],[@B41],[@B43],[@B50],[@B52],[@B59],[@B60]\] on SLE, MS, pSS, AA, PBC, HT, GBS, LN, vitiligo, T1D, IAA, and GD and correcting the errors in the previous meta-analyses. To our knowledge, this is the most comprehensive meta-analysis to assess the association of an *FAS* polymorphisms with the risk of autoimmune diseases, including SLE, RA, MS, AIH, LN, SSc, AA, pSS, HT, GBS, PBC, vitiligo, GD, T1D, IAA, JIA, and SPA.

Methods {#sec2}
=======

This meta-analysis was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 checklist \[[@B67]\].

Literature search {#sec2-1}
-----------------

Literature published in English and Chinese was retrieved from the PubMed, Embase, CNKI, and Wanfang databases up to December 2018. The search strategy used the following medical subject heading (MeSH) terms combined with text words: 'FAS or TNFRSF6 or CD95 or APO-1 or rs1800682 or rs2234767', 'polymorphism, genetic or polymorphisms or polymorphism or variant or mutation' and 'autoimmune diseases or autoimmune disease or autoimmunity'. A manual search of the reference lists was also performed to identify additional articles.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Studies meeting all the following criteria were included in the analysis: (1) evaluation of the association between the *FAS* −670 A/G or −1377 G/A polymorphisms and autoimmune diseases risk; (2) available and sufficient genotype data to calculate the odds ratio (OR) with 95% confidence interval (CI); and (3) a case--control study design.

Studies were excluded if they met the following criteria: (1) containing overlapping data; (2) not containing genotype data from the cases and controls; and (3) reviews, case reports, abstracts, letters, animal experiments and meta-analyses.

Data extraction {#sec2-3}
---------------

Two investigators independently assessed and extracted data from all included studies. Discrepancies were resolved by discussion. The following data were collected from each study: disease type, first author, year of publication, country, ethnicity, genotyping method, sample sizes of cases and controls, genotype frequencies in cases and controls, and *P*-value of test for Hardy--Weinberg equilibrium (HWE) in controls.

Quality evaluation {#sec2-4}
------------------

The methodological quality of the included studies was assessed independently by two investigators using the Newcastle--Ottawa scale (NOS) score \[[@B68]\]. The NOS score ranges from 0 to 9 and encompasses three components, including selection, comparability, and exposure. A study with score greater than or equal to 6 was considered of high methodological quality. Discrepancies were resolved by discussion.

Statistical analysis {#sec2-5}
--------------------

The chi-square test was applied to examine whether the observed genotype frequencies in controls conformed to HWE, and *P*\<0.05 was considered to deviate from HWE. The ORs with their 95% CIs were used to assess the strength of associations between the *FAS* −670 A/G and −1377 G/A polymorphisms and autoimmune diseases. The statistical significance of the pooled ORs was determined by the *Z* test. The allelic (*FAS* −670 A/G: G vs. A; *FAS* −1377 G/A: A vs. G), homozygous (*FAS* −670 A/G: GG vs. AA; *FAS* −1377 G/A: AA vs. GG), heterozygous (*FAS* −670 A/G: GG vs. GA; *FAS* −1377 G/A: AA vs. AG), dominant (*FAS* −670 A/G: GG + GA vs. AA; *FAS* −1377 G/A: AA+AG vs. GG), and recessive (*FAS* −670 A/G: GG vs. GA+ AA; *FAS* −1377 G/A: AA vs. AG+GG) models were examined. The between-studies heterogeneity was assessed by *Q* test and quantified by *I*^*2*^ test \[[@B69]\]. When *P*≥0.1 or *I^2^* \< 50%, there was no heterogeneity, and pooled OR estimates were combined using the fixed-effects model (Mantel--Haenszel method); otherwise, the random-effects model (Mantel--Haenszel method) was used to combine summary data \[[@B70]\]. To detect the main sources of heterogeneity, subgroup analyses were performed by ethnicity, disease type and quality score. Sensitivity analysis was carried out by excluding studies deviating from HWE to assess the stability of the meta-analysis. Egger's test was used to assess publication bias \[[@B71]\]. If there was publication bias, we recalculated the adjusted ORs using the trim-and-fill method \[[@B72]\] to evaluate the possible impact of publication bias. The trim-and-fill method was used to impute hypothetical missing studies. For significant results observed in the current meta-analysis, the false-positive report probability (FPRP) test was utilized to examine positive associations. An FPRP threshold of 0.5 and a prior probability of 0.1 were set to detect an OR of 0.67/1.50 (protective/risk effects) for an association with the tested genotypes. FPRP values less than 0.5 were considered as noteworthy associations \[[@B73]\]. All statistical analyses were conducted using Stata 15 software (Stata Corporation, College Station, TX, U.S.A.). Results with *P*\<0.05 were considered significant.

Trial sequential analysis {#sec2-6}
-------------------------

Traditional meta-analysis may yield type I errors due to dispersed data or repetitive significance testing when new studies are added to it \[[@B74],[@B75]\]. Trial sequential analysis (TSA) was used to minimize the risk of type I errors by calculating required information size (RIS) (meta-analysis sample size) and adjusted threshold for statistical significance \[[@B76]\]. TSA was performed by using TSA software 0.9.5.10 Beta (<http://www.ctu.dk/tsa/>) in the allelic model with the overall included studies by setting an overall type I error of 5%, power of 80%, relative risk reduction (RRR) of 20%, and control event proportion \[[@B77]\]. If the cumulative Z-curve crosses the trial sequential monitoring boundary or the RIS line, a reliable and conclusive evidence has been reached and further studies are not needed. Otherwise, more studies are needed to reach a firm conclusion.

Results {#sec3}
=======

Characteristics of the included studies {#sec3-1}
---------------------------------------

A flowchart of the selection of eligible articles is presented in [Figure 1](#F1){ref-type="fig"}. The initial search identified 2552 articles through the search strategy, and a total of 43 articles \[[@B15],[@B17],[@B20]\], consisting of 67 studies comprising 13340 patients and 14547 controls, were finally included in the meta-analysis according to the inclusion and exclusion criteria. Fifty-two studies examined the *FAS* −670 A/G polymorphism, and 15 studies examined the *FAS* −1377 G/A polymorphism. The characteristics of the articles included in the meta-analysis are summarized in [Table 1](#T1){ref-type="table"}.

![Flow diagram of the study selection process](bsr-40-bsr20191197-g1){#F1}

###### Characteristics of the case--control studies association of *FAS* −670A/G and −1377G/A polymorphisms and autoimmune diseases

  Disease type   Polymorphism   Author                    Year   Country          Ethnicity    Genotyping method   Sample size (case/control)   Case (GG/GA/AA)   Control (GG/GA/AA)   HWE   NOS                          
  -------------- -------------- ------------------------- ------ ---------------- ------------ ------------------- ---------------------------- ----------------- -------------------- ----- ----- ------ ----- --------- ---
  SLE            FAS −670A/G    Bollain et al.            2014   Mexico           Mestizos     PCR-RFLP            43/54                        16                13                   14    14    12     28    \<0.001   5
                                Moudi et al.              2013   Iran             Caucasian    PCR-RFLP            106/149                      17                55                   34    39    73     37    0.808     7
                                Molin et al.              2012   Germany          Caucasian    PCR                 46/96                        8                 21                   17    34    51     11    0.213     4
                                Lu et al.                 2012   China            Asian        PCR                 552/718                      96                237                  219   138   326    254   0.070     6
                                Pradhan et al.            2012   India            Indian       PCR-RFLP            70/70                        11                37                   22    21    42     7     0.036     6
                                Arasteh et al.            2010   Iran             Caucasian    ASO-PCR             249/212                      74                93                   82    58    98     56    0.273     7
                                Xu et al.                 2004   China            Asian        PCR-RFLP            103/110                      15                59                   29    23    61     26    0.249     5
                                Kanemitsu et al.          2002   Japan            Asian        AS-PCR, PCR-SSCP    109/140                      25                49                   35    50    64     26    0.492     5
                                Lee et al.                2001   Korea            Asian        PCR-RFLP            87/87                        13                47                   27    13    48     26    0.230     5
                                Huang et al.              1999   Australia        Caucasian    PCR-RFLP            79/86                        20                21                   38    20    22     44    \<0.001   4
  MS             FAS −670A/G    Mohammadzadeh et al.      2012   Iran             Caucasian    PCR-RFLP            107/112                      22                37                   48    18    50     44    0.551     8
                                Kantarci et al.           2004   U.S.A.           Caucasian    PCR-RFLP            218/441                      37                108                  73    86    234    121   0.154     8
                                Lucas et al.              2004   Spain            Caucasian    PCR                 320/218                      68                177                  75    44    113    61    0.525     7
                                Niino et al.              2002   Japan            Asian        PCR-RFLP            114/121                      23                65                   26    25    63     33    0.614     7
                                van Veen et al.           2002   Netherlands      Caucasian    PCR                 383/206                      80                185                  118   42    118    46    0.036     6
                                Huang et al.              2000   Australia        Caucasian    PCR-RFLP            124/183                      22                58                   44    40    97     46    0.407     7
  RA             FAS −670A/G    Yıldır et al.             2013   Turkey           Caucasian    TaqMan              100/101                      20                45                   35    22    40     39    0.063     7
                                Kobak et al.              2012   Turkey           Caucasian    PCR-RFLP            101/105                      24                50                   27    14    52     39    0.608     5
                                Mohammadzadeh et al.      2011   Iran             Caucasian    PCR                 120/112                      17                64                   39    18    50     44    0.551     4
                                Lee et al.                2001   Korea            Asian        PCR-RFLP            87/87                        16                38                   33    13    48     26    0.230     5
                                Huang et al.              1999   Australia        Caucasian    PCR-RFLP            185/86                       32                105                  48    22    44     20    0.825     4
                                Coakley et al.            1999   U.S.A.           Caucasian    PCR                 18/128                       4                 8                    6     31    61     36    0.607     4
  AIH            FAS −670A/G    Ngu et al.                2013   New Zealand      Caucasian    PCR                 77/455                       19                35                   23    107   214    134   0.232     5
                                Su et al.                 2012   China            Asian        PCR-RFLP            48/68                        5                 24                   19    20    30     18    0.335     6
                                Agarwal et al.            2007   U.S.A.           Caucasian    PCR                 149/172                      35                75                   39    32    84     56    0.960     4
                                Hiraide et al.            2005   Japan            Asian        PCR                 72/130                       14                31                   27    40    63     27    0.811     4
  LN             FAS −670A/G    Bollain et al.            2014   Mexico           Mestizos     PCR-RFLP            24/54                        8                 9                    7     14    12     28    \<0.001   5
                                Pradhan et al.            2012   India            Indian       PCR-RFLP            35/70                        7                 16                   12    21    42     7     0.036     6
                                Xu et al.                 2004   China            Asian        PCR-RFLP            62/110                       9                 34                   19    23    61     26    0.249     5
                                Lee et al.                2001   Korea            Asian        PCR-RFLP            26/87                        4                 12                   10    13    48     26    0.230     5
  SSc            FAS −670A/G    Liakouli et al.           2013   Italy            Caucasian    PCR                 350/232                      65                158                  127   60    120    52    0.586     8
                                Broen et al.              2009   Europe, U.S.A.   Caucasian    TaqMan              2565/2855                    616               1205                 744   586   1455   814   0.168     7
                                Broen et al.              2009   U.S.A.           Hispanic     TaqMan              159/137                      46                80                   33    41    71     25    0.552     7
                                Broen et al.              2009   U.S.A.           African      TaqMan              176/194                      93                68                   15    96    83     15    0.613     7
  AA             FAS −670A/G    Seleit et al.             2018   Egypt            Caucasian    PCR                 60/40                        14                37                   9     4     23     13    0.181     8
                                Kalkan et al.             2013   Turkey           Caucasian    PCR-RFLP            118/118                      0                 81                   37    13    65     40    0.077     7
                                Fan et al.                2010   China            Asian        PCR                 84/84                        13                35                   36    13    49     22    0.099     6
  pSS            FAS −670A/G    Treviño-Talavera et al.   2014   Mexico           Amerindian   PCR-RFLP            77/84                        25                32                   20    22    42     20    0.996     4
                                Mullighan et al.          2004   Australia        Caucasian    PCR                 101/108                      17                54                   30    21    54     33    0.897     4
                                Bolstad et al.            2000   Norway           Caucasian    PCR                 70/72                        26                26                   18    12    39     21    0.394     5
  HT             FAS −670A/G    Erdogan et al.            2016   Turkey           Caucasian    PCR-RFLP            112/112                      31                57                   24    15    56     41    0.547     8
                                Inoue et al.              2016   Japan            Asian        PCR-RFLP            117/80                       33                53                   31    20    37     23    0.510     6
  GBS            FAS −670A/G    Islam et al.              2018   Japan            Asian        PCR                 300/300                      51                114                  135   45    126    129   0.125     7
                                Geleijns et al.           2005   Netherlands      Caucasian    PCR                 272/212                      67                129                  76    42    114    56    0.243     5
  PBC            FAS −670A/G    Su et al.                 2012   China            Asian        PCR-RFLP            19/68                        5                 7                    7     20    30     18    0.335     6
                                Hiraide et al.            2005   Japan            Asian        PCR                 96/130                       30                37                   29    40    63     27    0.811     4
  vitiligo       FAS −670A/G    Li et al.                 2008   China            Asian        PCR                 750/756                      101               364                  285   108   363    285   0.660     7
  GD             FAS −670A/G    Inoue et al.              2016   Japan            Asian        PCR-RFLP            146/80                       41                61                   44    20    37     23    0.510     6
  T1D            FAS −670A/G    Sahin et al.              2012   Turkey           Caucasian    PCR                 85/80                        13                46                   26    10    40     30    0.551     7
  IAA            FAS −670A/G    Rehman et al.             2018   Pakistan         Caucasian    PCR                 170/222                      13                105                  52    26    47     149   \<0.001   7
  JIA            FAS −670A/G    Donn et al.               2002   U.K.             Caucasian    PCR-RFLP            342/255                      79                177                  86    48    139    68    0.122     4
  SPA            FAS −670A/G    Lee et al.                2001   Korea            Asian        PCR                 54/84                        11                27                   16    13    46     25    0.279     5
                                                                                                                                                Case (AA/AG/GG)   Control (AA/AG/GG)                                      
  SLE            FAS −1377A/G   Arasteh et al.            2010   Iran             Caucasian    ASO-PCR             249/212                      3                 43                   203   6     54     152   0.652     7
                                Kanemitsu et al.          2002   Japan            Asian        AS-PCR, PCR-SSCP    109/140                      25                42                   42    33    62     45    0.202     5
                                Huang et al.              2000   Australia        Caucasian    PCR                 86/90                        3                 21                   62    2     22     66    0.917     7
  RA             FAS −1377A/G   Zhu et al.                2016   China            Asian        MALDI-TOFMS         615/839                      68                284                  246   85    357    389   0.817     7
                                Yıldır et al.             2013   Turkey           Caucasian    TaqMan              100/101                      0                 26                   74    2     18     81    0.411     7
  pSS            FAS −1377A/G   Mullighan et al.          2004   Australia        Caucasian    PCR                 101/108                      4                 14                   83    1     19     88    0.982     4
                                Bolstad et al.            2000   Norway           Caucasian    PCR                 70/72                        2                 18                   50    1     18     53    0.702     5
  GBS            FAS −1377A/G   Islam et al.              2018   Japan            Asian        PCR                 300/300                      12                105                  183   9     93     198   0.627     7
                                Geleijns et al.           2005   Netherlands      Caucasian    PCR                 272/212                      3                 61                   208   1     40     171   0.406     5
  Vitiligo       FAS −1377A/G   Li et al.                 2008   China            Asian        PCR                 750/756                      100               378                  272   82    346    328   0.514     7
  IAA            FAS −1377A/G   Rehman et al.             2018   Pakistan         Caucasian    PCR                 170/222                      26                23                   121   31    39     152   \<0.001   7
  HT             FAS −1377A/G   Inoue et al.              2016   Japan            Asian        PCR-RFLP            123/87                       26                61                   36    13    40     34    0.826     6
  GD             FAS −1377A/G   Inoue et al.              2016   Japan            Asian        PCR-RFLP            160/87                       27                78                   55    13    40     34    0.826     6
  AIH            FAS −1377A/G   Hiraide et al.            2005   Japan            Asian        PCR                 74/98                        13                28                   33    25    39     34    0.051     4
  AA             FAS −1377A/G   Fan et al.                2010   China            Asian        PCR                 84/84                        12                32                   40    7     42     35    0.252     6

Meta-analysis results of the *FAS* −670 A/G and −1377 G/A polymorphisms and autoimmune diseases {#sec3-2}
-----------------------------------------------------------------------------------------------

A summary of the meta-analysis of the association between the *FAS* −670 A/G and −1377 G/A polymorphisms and autoimmune diseases is shown in [Table 2](#T2){ref-type="table"}. In the *FAS* −670 A/G polymorphism, a significant association between *FAS* −670 A/G and the risk of autoimmune diseases was observed under the heterozygous genetic model (GG vs. GA: OR = 1.079, 95% CI 1.004--1.160, *P*=0.038). In the *FAS* −1377 G/A polymorphism, our results indicated that *FAS* −1377 G/A polymorphism was associated with the risk of autoimmune diseases (A vs. G: OR = 1.11, 95% CI = 1.03--1.20, *P*=0.008; AA vs. GG: OR = 1.23, 95% CI = 1.03--1.47, *P*=0.024; AA+AG vs. GG: OR = 1.14, 95% CI = 1.02--1.26, *P*=0.015).

###### Meta-analysis for the association between *FAS* −670A/G and −1377G/A polymorphisms and autoimmune diseases stratified by ethnicity, disease type and quality score

  Polymorphism                   Categories     Studies (*n*)   Test of heterogeneity   Test of associations   Egger's test           Sensitivity analysis           
  ------------------------------ -------------- --------------- ----------------------- ---------------------- ---------------------- ---------------------- ------- ---------
  *FAS* −670 A/G G vs. A                                                                                                                                             
                                 Overall        52              \<0.001                 65.9                   0.99 (0.95, 1.03)      0.493                  0.222   0.295
                                 Caucasian      27              \<0.001                 71.5                   1.03 (0.98, 1.08)      0.241                  0.973   0.418
                                 Asian          18              0.225                   19.2                   0.89 (0.83, 0.96)      0.002                  0.147   0.002
                                 High quality   28              \<0.001                 70.9                   0.98 (0.94, 1.03)      0.446                  0.314   0.427
                                 Low quality    24              \<0.001                 59.3                   1.00 (0.93, 1.08)      0.958                  0.622   0.328
                                 SLE            10              \<0.001                 73.6                   0.85 (0.77, 0.94)      0.001                  0.583   \<0.001
                                 RA             6               0.264                   22.6                   1.04 (0.88, 1.23)      0.675                  0.772   0.675
                                 MS             6               0.313                   15.7                   0.92 (0.82, 1.03)      0.148                  0.826   0.348
                                 AIH            4               0.003                   78.2                   0.89 (0.74, 1.08)      0.232                  0.089   0.232
                                 LN             4               0.041                   63.6                   0.82 (0.62, 1.08)      0.159                  0.531   0.201
                                 SSc            4               0.002                   80.2                   1.01 (0.95, 1.09)      0.707                  0.419   0.707
                                 AA             3               0.024                   73.3                   0.93 (0.72, 1.19)      0.553                  0.372   0.553
                                 pSS            3               0.692                   0.0                    1.02 (0.76, 1.36)      0.914                  0.285   0.914
                                 HT             2               0.082                   67.0                   1.45 (1.10, 1.90)      0.008                  NA      0.008
                                 GBS            2               0.709                   0.0                    1.03 (0.87, 1.23)      0.729                  NA      0.729
                                 PBC            2               0.828                   0.0                    0.82 (0.59, 1.14)      0.240                  NA      0.240
  *FAS* −670 A/G GG vs. AA                                                                                                                                           
                                 Overall        52              \<0.001                 59.1                   0.96 (0.89, 1.04)      0.288                  0.104   0.375
                                 Caucasian      27              \<0.001                 63.8                   1.03 (0.94, 1.14)      0.524                  0.519   0.368
                                 Asian          18              0.225                   19.2                   0.81 (0.70, 0.94)      0.005                  0.196   0.005
                                 High quality   28              \<0.001                 62.6                   0.95 (0.86, 1.04)      0.244                  0.078   0.556
                                 Low quality    24              \<0.001                 56.1                   0.99 (0.85, 1.16)      0.905                  0.287   0.304
                                 SLE            10              \<0.001                 73.2                   0.74 (0.61, 0.89)      0.002                  0.230   \<0.001
                                 RA             6               0.263                   22.7                   1.05 (0.75, 1.48)      0.762                  0.930   0.762
                                 MS             6               0.353                   9.9                    0.87 (0.69, 1.10)      0.239                  0.686   0.467
                                 AIH            4               0.004                   77.2                   0.80 (0.56, 1.15)      0.232                  0.123   0.232
                                 LN             4               0.036                   65.0                   0.68 (0.39, 1.18)      0.173                  0.843   0.226
                                 SSc            4               0.002                   79.1                   1.04 (0.91, 1.19)      0.567                  0.342   0.567
                                 AA             3               0.003                   82.9                   0.68 (0.36, 1.28)      0.235                  0.805   0.235
                                 pSS            3               0.683                   0.0                    1.00 (0.56, 1.79)      0.998                  0.044   0.286
                                 HT             2               0.062                   71.4                   2.05 (1.19, 3.54)      0.010                  NA      0.010
                                 GBS            2               0.818                   0.0                    1.12 (0.79, 1.59)      0.510                  NA      0.510
                                 PBC            2               0.913                   0.0                    0.69 (0.37, 1.28)      0.234                  NA      0.234
  *FAS* −670 A/G GG vs. GA                                                                                                                                           
                                 Overall        52              0.018                   31.4                   1.079 (1.004, 1.160)   0.038                  0.087   0.006
                                 Caucasian      27              \<0.001                 54.4                   1.12 (1.03, 1.23)      0.012                  0.008   0.001
                                 Asian          18              0.835                   0.0                    0.99 (0.86, 1.14)      0.905                  0.991   0.905
                                 High quality   28              0.003                   47.3                   1.07 (0.99, 1.17)      0.096                  0.022   0.028
                                 Low quality    24              0.454                   0.5                    1.10 (0.95, 1.27)      0.208                  0.364   0.180
                                 SLE            10              0.568                   0.0                    0.92 (0.77, 1.11)      0.398                  0.177   0.493
                                 RA             6               0.276                   20.9                   0.96 (0.69, 1.31)      0.781                  0.497   0.781
                                 MS             6               0.766                   0.0                    1.05 (0.85, 1.30)      0.674                  0.627   0.995
                                 AIH            4               0.151                   43.5                   0.90 (0.64, 1.27)      0.563                  0.005   0.563
                                 LN             4               0.910                   0.0                    0.83 (0.49, 1.39)      0.471                  0.142   0.621
                                 SSc            4               0.243                   28.2                   1.20 (1.07, 1.36)      0.003                  0.201   0.003
                                 AA             3               0.009                   78.7                   0.79 (0.44, 1.41)      0.419                  0.355   0.419
                                 pSS            3               0.252                   23.9                   1.10 (0.66, 1.85)      0.715                  0.358   0.071
                                 HT             2               0.267                   18.9                   1.52 (0.93, 2.50)      0.098                  NA      0.098
                                 GBS            2               0.726                   0.0                    1.33 (0.96, 1.85)      0.089                  NA      0.089
                                 PBC            2               0.809                   0.0                    1.23 (0.71, 2.16)      0.461                  NA      0.461
  *FAS* −670 A/G GG+GA vs. AA                                                                                                                                        
                                 Overall        52              \<0.001                 70.6                   0.94 (0.89, 1.00)      0.051                  0.129   0.004
                                 Caucasian      27              \<0.001                 76.0                   1.00 (0.93, 1.08)      0.945                  0.662   0.306
                                 Asian          18              0.143                   26.7                   0.83 (0.74, 0.92)      0.001                  0.056   0.001
                                 High quality   28              \<0.001                 76.7                   0.94 (0.88, 1.01)      0.071                  0.614   0.023
                                 Low quality    24              \<0.001                 60.1                   0.95 (0.85, 1.08)      0.445                  0.500   0.050
                                 SLE            10              \<0.001                 74.3                   0.78 (0.67, 0.90)      0.001                  0.374   \<0.001
                                 RA             6               0.388                   4.4                    1.09 (0.85, 1.40)      0.503                  0.388   0.503
                                 MS             6               0.080                   49.1                   0.83 (0.70, 0.99)      0.043                  0.752   0.261
                                 AIH            4               0.026                   67.6                   0.87 (0.65, 1.15)      0.330                  0.170   0.330
                                 LN             4               \<0.001                 84.2                   0.86 (0.57, 1.31)      0.483                  0.922   0.196
                                 SSc            4               0.014                   71.7                   0.92 (0.82, 1.02)      0.112                  0.424   0.112
                                 AA             3               0.009                   78.5                   0.95 (0.66, 1.39)      0.804                  0.666   0.804
                                 pSS            3               0.741                   0.0                    0.98 (0.62, 1.54)      0.921                  0.964   0.874
                                 HT             2               0.150                   51.7                   1.58 (1.03, 2.42)      0.037                  NA      0.037
                                 GBS            2               0.988                   0.0                    0.92 (0.72, 1.19)      0.536                  NA      0.536
                                 PBC            2               0.976                   0.0                    0.61 (0.36, 1.03)      0.066                  NA      0.066
  *FAS* −670 A/G GG vs. GA+AA                                                                                                                                        
                                 Overall        52              0.003                   38.8                   1.04 (0.97, 1.11)      0.294                  0.083   0.142
                                 Caucasian      27              0.001                   52.7                   1.10 (1.01, 1.19)      0.035                  0.175   0.011
                                 Asian          18              0.694                   0.0                    0.91 (0.80, 1.04)      0.162                  0.541   0.162
                                 High quality   28              0.005                   45.3                   1.03 (0.95, 1.12)      0.457                  0.019   0.226
                                 Low quality    24              0.066                   32.2                   1.06 (0.93, 1.21)      0.421                  0.284   0.638
                                 SLE            10              0.065                   44.1                   0.86 (0.72, 1.01)      0.071                  0.292   0.034
                                 RA             6               0.237                   26.4                   0.99 (0.74, 1.34)      0.962                  0.627   0.962
                                 MS             6               0.824                   0.0                    0.97 (0.80, 1.19)      0.796                  0.714   0.709
                                 AIH            4               0.027                   67.3                   0.86 (0.63, 1.18)      0.345                  0.060   0.345
                                 LN             4               0.895                   0.0                    0.71 (0.43, 1.15)      0.162                  0.193   0.303
                                 SSc            4               0.028                   67.2                   1.14 (1.02, 1.28)      0.022                  0.275   0.022
                                 AA             3               0.009                   79.0                   0.77 (0.44, 1.34)      0.349                  0.546   0.349
                                 pSS            3               0.338                   0.0                    1.07 (0.66, 1.75)      0.081                  0.426   0.081
                                 HT             2               0.122                   58.1                   1.68 (1.06, 2.68)      0.029                  NA      0.029
                                 GBS            2               0.678                   0.0                    1.24 (0.91, 1.69)      0.172                  NA      0.172
                                 PBC            2               0.787                   0.0                    0.99 (0.66, 1.75)      0.960                  NA      0.960
  *FAS* −1377 G/A A vs. G                                                                                                                                            
                                 Overall        15              0.091                   34.6                   1.11 (1.03, 1.20)      0.008                  0.329   0.006
                                 Caucasian      7               0.173                   33.4                   0.98 (0.82, 1.16)      0.790                  0.357   0.863
                                 Asian          8               0.198                   28.8                   1.15 (1.05, 1.25)      0.002                  0.167   0.002
                                 High quality   10              0.116                   36.5                   1.14 (1.05, 1.24)      0.002                  0.285   0.001
                                 Low quality    5               0.293                   19.2                   0.96 (0.79, 1.18)      0.711                  0.588   0.711
  *FAS* −1377 G/A AA vs. GG                                                                                                                                          
                                 Overall        15              0.452                   0.0                    1.23 (1.03, 1.47)      0.024                  0.878   0.020
                                 Caucasian      7               0.459                   0.0                    1.06 (0.67, 1.66)      0.816                  0.752   0.881
                                 Asian          8               0.353                   10.0                   1.27 (1.04, 1.54)      0.018                  0.511   0.018
                                 High quality   10              0.702                   0.0                    1.31 (1.08, 1.59)      0.007                  0.234   0.005
                                 Low quality    5               0.325                   14.1                   0.86 (0.54, 1.38)      0.536                  0.072   0.536
  *FAS* −1377 G/A AA vs. AG                                                                                                                                          
                                 Overall        15              0.863                   0.0                    1.12 (0.93, 1.34)      0.234                  0.584   0.323
                                 Caucasian      7               0.570                   0.0                    1.30 (0.76, 2.20)      0.335                  0.883   0.680
                                 Asian          8               0.858                   0.0                    1.09 (0.90, 1.33)      0.360                  0.444   0.360
                                 High quality   10              0.820                   0.0                    1.12 (0.92, 1.36)      0.268                  0.958   0.375
                                 Low quality    5               0.507                   0.0                    1.11 (0.70, 1.77)      0.662                  0.166   0.662
  *FAS* −1377 G/A AA+AG vs. GG                                                                                                                                       
                                                                                                                                                                     
                                 Overall        15              0.055                   39.9                   1.14 (1.02, 1.26)      0.015                  0.113   0.008
                                 Caucasian      7               0.190                   31.1                   0.95 (0.78, 1.16)      0.620                  0.366   0.798
                                 Asian          8               0.157                   34.0                   1.21 (1.07, 1.36)      0.002                  0.080   0.002
                                 High quality   10              0.047                   47.5                   1.17 (1.05, 1.31)      0.005                  0.257   0.002
                                 Low quality    5               0.402                   0.7                    0.96 (0.74, 1.23)      0.727                  0.560   0.727
  *FAS* −1377 G/A AA vs. AG+GG                                                                                                                                       
                                 Overall        15              0.741                   0.0                    1.16 (0.98, 1.37)      0.090                  0.888   0.097
                                 Caucasian      7               0.490                   0.0                    1.10 (0.70, 1.72)      0.674                  0.823   0.834
                                 Asian          8               0.683                   0.0                    1.17 (0.97, 1.40)      0.098                  0.959   0.098
                                 High quality   10              0.823                   0.0                    1.20 (0.99, 1.44)      0.054                  0.444   0.056
                                 Low quality    5               0.392                   2.5                    0.96 (0.63, 1.47)      0.848                  0.120   0.848

Stratification analyses by ethnicity, disease type, and quality score {#sec3-3}
---------------------------------------------------------------------

Based on ethnicity, disease type, and quality score, we performed stratification analyses.

The results of the meta-analysis of the association between the *FAS* −670 A/G and −1377 G/A polymorphisms and autoimmune diseases risk stratified by ethnicity, disease type, and quality score are shown in [Table 2](#T2){ref-type="table"}.

On the basis of ethnicity, the stratified meta-analysis showed an association between *FAS* −670 A/G polymorphism and the risk of autoimmune diseases in Caucasians (GG vs. GA: OR = 1.12, 95% CI 1.03--1.23, *P*=0.012) and Asians (G vs. A: OR = 0.89, 95% CI 0.83--0.96, *P*=0.002) but not in other ethnic groups. The association between *FAS* −1377 G/A polymorphism and the risk of autoimmune diseases was observed in Asians (A vs. G: OR = 1.15, 95% CI 1.05--1.25, *P*=0.002) but not in Caucasians.

On the basis of disease type, the stratified meta-analysis suggested that the *FAS* −670 A/G polymorphism might be associated with the risk of SLE (G vs. A: OR = 0.85, 95% CI 0.77--0.94, *P*=0.001), MS (GG+GA vs. AA: OR = 0.83, 95% CI 0.70--0.99, *P*=0.043), SSc (GG vs. GA: OR = 1.20, 95% CI 1.07--1.36, *P*=0.003), and HT (G vs. A: OR = 1.45, 95% CI 1.10--1.90, *P*=0.008). However, no association was observed between the *FAS* −670A/G polymorphism and the risk of RA, AIH, AA, pSS, GBS, PBC, or LN. For *FAS* −1377 G/A polymorphism, subgroup analysis was not performed owing to the limited study number.

On the basis of quality score, the stratified meta-analysis suggested that the *FAS* −670 A/G polymorphism might not be associated with autoimmune diseases in high- or low-quality studies. However, the association between *FAS* −1377 G/A polymorphism and the risk of autoimmune diseases was observed in high-quality studies (A vs. G: OR = 1.14, 95% CI 1.05--1.24, *P*=0.002) but not in low-quality studies.

Stratification analysis showed that ethnicity, disease type, and quality score might be the factors of heterogeneity across all studies of association between *FAS* −670 A/G polymorphism and autoimmune diseases risk, and quality score may be the factor of heterogeneity across all studies of association between *FAS* −1377 G/A polymorphism and autoimmune diseases risk.

Stratification analysis by ethnicity for SLE, RA, MS, AIH, LN, SSc, AA, and pSS {#sec3-4}
-------------------------------------------------------------------------------

The associations between the *FAS* −670 A/G polymorphism and SLE, RA, MS, AIH, LN, SSc, AA, and pSS are summarized in [Table 3](#T3){ref-type="table"} (for *FAS* −1377 G/A polymorphism, subgroup analysis was not performed owing to the limited study number). An association between the *FAS* −670 A/G polymorphism and the risk of autoimmune diseases was observed in Asian patients with SLE (G vs. A: OR = 0.84, 95% CI 0.74--0.95, *P*=0.007) or AIH (G vs. A: OR = 0.55, 95% CI 0.40--0.76, *P*\<0.001) and in Caucasian patients with SLE (G vs. A: OR = 0.80, 95% CI 0.67--0.96, *P*=0.015), MS (GG+GA vs. AA: OR = 0.80, 95% CI 0.66--0.96, *P*=0.018), or SSc (GG vs. GA: OR = 1.22, 95% CI 1.07--1.39, *P*=0.003). However, no significant risk was found in any specific ethnicity for RA, LN, AA, or pSS.

###### Meta-analysis for the association between *FAS* −670 A/G polymorphism and SLE, RA, MS, AIH, LN, SSc, AA, and pSS stratified by ethnicity

  Diseases   FAS −670A/G polymorphism   Population   Studies (*n*)   Test of heterogeneity   Test of associations   Egger's test *P-*value   Power analysis (%)   Sensitivity analysis value          
  ---------- -------------------------- ------------ --------------- ----------------------- ---------------------- ------------------------ -------------------- ---------------------------- ------ ---------
  SLE                                                                                                                                                                                                 
             G vs. A                    Caucasian    4               0.017                   70.7                   0.80 (0.67, 0.96)        0.015                0.634                        73.1   0.015
                                        Asian        4               0.296                   18.9                   0.84 (0.74, 0.95)        0.007                0.634                        80.2   0.007
             GG vs. AA                  Caucasian    4               0.011                   73.2                   0.68 (0.49, 0.94)        0.021                0.279                        63.9   0.021
                                        Asian        4               0.209                   33.9                   0.71 (0.55, 0.92)        0.010                0.545                        72.9   0.010
             GG vs. GA                  Caucasian    4               0.130                   46.9                   0.96 (0.70, 1.31)        0.797                0.288                        5.1    0.797
                                        Asian        4               0.848                   0.0                    0.93 (0.72, 1.18)        0.537                0.600                        13.7   0.537
             GG+GA vs. AA               Caucasian    4               0.027                   67.4                   0.70 (0.54, 0.92)        0.011                0.442                        81.6   0.011
                                        Asian        4               0.091                   53.6                   0.77 (0.63, 0.93)        0.007                0.581                        76.7   0.007
             GG vs. GA+AA               Caucasian    4               0.056                   60.4                   0.84 (0.63, 1.12)        0.228                0.272                        19.2   0.228
                                        Asian        4               0.767                   0.0                    0.83 (066, 1.05)         0.118                0.551                        40.4   0.118
  RA                                                                                                                                                                                                  
             G vs. A                    Caucasian    5               0.197                   33.7                   1.06 (0.88, 1.27)        0.520                0.838                        5.7    0.149
             GG vs. AA                  Caucasian    5               0.169                   37.8                   1.07 (0.74, 1.55)        0.723                0.956                        8.6    0.250
             GG vs. GA                  Caucasian    5               0.309                   16.6                   0.88 (0.62, 1.24)        0.471                0.633                        21.4   0.941
             GG+GA vs. AA               Caucasian    5               0.568                   0.0                    1.19 (0.90, 1.56)        0.221                0.376                        27.6   0.103
             GG vs. GA+AA               Caucasian    5               0.178                   36.5                   0.95 (0.69, 1.32)        0.764                0.737                        10.1   0.764
  MS                                                                                                                                                                                                  
             G vs. A                    Caucasian    5               0.282                   20.9                   0.90 (0.80, 1.02)        0.095                0.863                        23.3   0.242
             GG vs. AA                  Caucasian    5               0.296                   18.6                   0.84 (0.66, 1.08)        0.172                0.981                        10.4   0.356
             GG vs. GA                  Caucasian    5               0.678                   0.0                    1.07(0.85, 1.34)         0.576                0.410                        17.7   0.899
             GG+GA vs. AA               Caucasian    5               0.103                   48.1                   0.80 (0.66, 0.96)        0.018                0.754                        49.9   0.139
             GG vs. GA+AA               Caucasian    5               0.703                   0.0                    0.97 (0.79, 1.20)        0.809                0.710                        5.0    0.716
  LN                                                                                                                                                                                                  
             G vs. A                    Asian        2               0.796                   0.0                    0.79 (0.55, 1.14)        0.201                NA                           19.7   0.201
             GG vs. AA                  Asian        2               0.634                   0.0                    0.62 (0.28, 1.35)        0.226                NA                           18.7   0.226
             GG vs. GA                  Asian        2               0.480                   0.0                    0.83 (0.40, 1.72)        0.621                NA                           6.7    0.621
             GG+GA vs. AA               Asian        2               0.964                   0.0                    0.69 (0.40, 1.21)        0.196                NA                           21.3   0.196
             GG vs. GA+AA               Asian        2               0.528                   0.0                    0.75 (0.37, 1.49)        0.407                NA                           10.3   0.407
  SSc                                                                                                                                                                                                 
             G vs. A                    Caucasian    2               \<0.001                 93.3                   1.01 (0.94, 1.09)        0.688                NA                           6.3    0.688
             GG vs. AA                  Caucasian    2               \<0.001                 92.8                   1.05 (0.91, 1.22)        0.476                NA                           84.1   0.476
             GG vs. GA                  Caucasian    2               0.056                   72.6                   1.22 (1.07, 1.39)        0.003                NA                           10.3   0.003
             GG+GA vs. AA               Caucasian    2               0.001                   90.5                   0.92 (0.82, 1.03)        0.137                NA                           33.6   0.137
             GG vs. GA+AA               Caucasian    2               0.003                   88.4                   1.15 (1.02, 1.30)        0.021                NA                           64.5   0.021
  AIH                                                                                                                                                                                                 
             G vs. A                    Caucasian    2               0.368                   0.0                    1.14 (0.91, 1.43)        0.265                NA                           13.4   0.265
                                        Asian        2               0.786                   0.0                    0.55 (0.40, 0.76)        \<0.001              NA                           95.9   \<0.001
             GG vs. AA                  Caucasian    2               0.369                   0.0                    1.29 (0.82, 2.02)        0.276                NA                           5.9    0.276
                                        Asian        2               0.591                   0.0                    0.31 (0.16, 0.60)        \<0.001              NA                           51.7   \<0.001
             GG vs. GA                  Caucasian    2               0.776                   0.0                    1.16 (0.76, 1.75)        0.489                NA                           13.1   0.489
                                        Asian        2               0.230                   30.7                   0.54 (0.29, 1.00)        0.051                NA                           95.4   0.051
             GG+GA vs. AA               Caucasian    2               0.369                   0.0                    1.17 (0.82, 1.68)        0.384                NA                           12.6   0.384
                                        Asian        2               0.658                   0.0                    0.48 (0.29, 0.79)        0.004                NA                           84.2   0.004
             GG vs. GA+AA               Caucasian    2               0.560                   0.0                    1.20 (0.82, 1.77)        0.350                NA                           8.5    0.350
                                        Asian        2               0.303                   5.7                    0.44 (0.25, 0.78)        0.005                NA                           84.3   0.005
  AA                                                                                                                                                                                                  
             G vs. A                    Caucasian    2               0.021                   81.2                   1.06 (0.78, 1.45)        0.703                NA                           9.7    0.703
             GG vs. AA                  Caucasian    2               0.001                   91.1                   0.75 (0.32, 1.74)        0.496                NA                           25.0   0.496
             GG vs. GA                  Caucasian    2               0.002                   89.3                   0.50 (0.22, 1.10)        0.086                NA                           5.2    0.086
             GG+GA vs. AA               Caucasian    2               0.118                   59.2                   1.39 (0.87, 2.23)        0.172                NA                           34.0   0.172
             GG vs. GA+AA               Caucasian    2               0.001                   90.1                   0.61 (0.29, 1.32)        0.211                NA                           15.2   0.211
  pSS                                                                                                                                                                                                 
             G vs. A                    Caucasian    2               0.096                   64.0                   1.19 (0.88, 1.60)        0.252                NA                           20.7   0.252
             GG vs. AA                  Caucasian    2               0.097                   63.7                   1.40 (0.77, 2.55)        0.273                NA                           32.5   0.273
             GG vs. GA                  Caucasian    2               0.015                   83.0                   1.49 (0.87, 2.56)        0.144                NA                           24.4   0.144
             GG+GA vs. AA               Caucasian    2               0.783                   0.0                    1.10 (0.69, 1.74)        0.694                NA                           6.8    0.694
             GG vs. GA+AA               Caucasian    2               0.020                   81.7                   1.49 (0.89, 2.47)        0.128                NA                           34.0   0.128

Abbreviation: NA, not available.

Publication bias {#sec3-5}
----------------

The Egger's test was performed to assess the publication bias under all genetic models of the meta-analysis and the results are shown in [Table 2](#T2){ref-type="table"}. For the *FAS* −670 A/G polymorphism, the results from Egger's tests indicated evidence for publication bias in the homozygous model for pSS, heterozygous models for Caucasians, AIH and high-quality studies, and recessive models for high-quality studies (*P*=0.044, 0.008, 0.005, 0.022, and 0.019, respectively). After adjustment by the trim-and-fill method, the ORs corrected for publication bias were not qualitatively different for the five models (OR = 1.30, 95% CI = 0.79--2.13, *P*=0.298; OR = 1.13, 95% CI = 1.03--1.23, *P*=0.007; OR = 0.92, 95% CI = 0.65--1.30, *P*=0.636; OR = 1.09, 95% CI = 1.00--1.18, *P*=0.052; and OR = 1.04, 95% CI = 0.96--1.13, *P*=0.323, respectively). No publication bias was found among the studies regarding the association between *Fas* −1377 G/A polymorphism and autoimmune diseases risk (all *P*\>0.05). Therefore, the presence of publication bias did not influence the stability of the results. In addition, the results concerning association between *FAS* −670 A/G polymorphism and SLE, RA, MS, AIH, LN, SSc, AA, and pSS stratified by ethnicity did not show any evidence of publication bias ([Table 3](#T3){ref-type="table"}).

Sensitivity analysis {#sec3-6}
--------------------

The genotype frequencies in the controls of five articles \[[@B22],[@B31],[@B51],[@B52],[@B55]\] deviated significantly from the HWE, which could cause potential bias. To check the robustness of our results, sensitivity analysis was performed by excluding these five HWE-deviating studies. The corresponding results of the sensitivity analysis are provided in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. The results showed that the overall OR changed only under the dominant model (*P*=0.051 vs. 0.004) after excluding the HWE-deviating studies, but the association between the *FAS* −670 A/G polymorphism and autoimmune diseases risk was not qualitatively altered under the heterozygous model (*P*=0.038 vs. 0.006), illustrating that the meta-analysis results were stable. In the stratification analysis by ethnicity, the results in Caucasians and Asians did not change when the HWE-deviating studies were excluded. In the stratification analysis by disease type, the OR changed only under the recessive model (*P*=0.071 vs. 0.034) after excluding the HWE-deviating studies from the analysis of SLE, but the association between the *FAS* −670 A/G polymorphism and SLE risk was not qualitatively altered under the allelic model (*P*=0.001 vs. \<0.001). However, the association between *FAS* −670 A/G and MS risk was materially altered under the dominant model (*P*=0.043 vs. 0.261) after excluding the HWE-deviating studies. Similarly, a change was observed in the analysis of Caucasian patients with MS under the dominant model (*P*=0.018 vs. 0.139). In the stratification analysis by quality score, the association between *FAS* −670 A/G and high-quality studies was materially altered under the heterozygous and dominant model (*P*=0.096 vs. 0.028; *P*=0.071 vs. 0.023) after excluding the HWE-deviating studies. Additionally, the results of the association between *FAS* −1377 G/A and autoimmune diseases risk did not change when the HWE-deviating studies were excluded in five models.

FPRP analysis results {#sec3-7}
---------------------

The FPRP values were calculated for the main significant associations and the results are shown in [Table 4](#T4){ref-type="table"}. For a prior probability of 0.1, the FPRP values indicated that four genetic models (*FAS* −670 A/G: GG vs. GA; *FAS* −1377 G/A: A vs. G; *FAS* −1377 G/A: AA vs. GG; *FAS* −1377 G/A: AA+AG vs. GG) of the *FAS* −670 A/G and −1377 G/A polymorphisms were truly associated with an increased risk of autoimmune diseases (FPRP = 0.262, 0.073, 0.173, and 0.085, respectively). Furthermore, with regard to the *FAS* −670 A/G polymorphism, noteworthy results were found in Asians, Caucasians, SLE, HT, SSc, and MS. Regarding the *FAS* −1377 G/A polymorphism, a positive association was observed in Asians and high-quality studies.

###### FPRP values for associations between *FAS* −670A/G and −1377G/A polymorphisms and autoimmune disease PRISMA 2009 Checklist

  Genotype                     Population     Studies (*n*)   OR (95% CI)            *P*-value[^1^](#T4TFN1){ref-type="table-fn"}   Statistical power[^2^](#T4TFN2){ref-type="table-fn"}   Prior probability                                                                                                                                                           
  ---------------------------- -------------- --------------- ---------------------- ---------------------------------------------- ------------------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ -------
  FAS −670 A/G G vs. A                                                                                                                                                                                                                                                                                                                                                 
                               Asian          18              0.89 (0.83, 0.96)      0.003                                          1.000                                                  0.008[^3^](#T4TFN3){ref-type="table-fn"}   0.022[^3^](#T4TFN3){ref-type="table-fn"}   0.202[^3^](#T4TFN3){ref-type="table-fn"}   0.718                                      0.962
                               SLE            10              0.85 (0.77, 0.94)      0.002                                          1.000                                                  0.005[^3^](#T4TFN3){ref-type="table-fn"}   0.014[^3^](#T4TFN3){ref-type="table-fn"}   0.133[^3^](#T4TFN3){ref-type="table-fn"}   0.608                                      0.939
                               HT             2               1.45 (1.10, 1.90)      0.007                                          0.597                                                  0.034[^3^](#T4TFN3){ref-type="table-fn"}   0.096[^3^](#T4TFN3){ref-type="table-fn"}   0.539                                      0.922                                      0.992
  FAS −670 A/G GG vs. AA                                                                                                                                                                                                                                                                                                                                               
                               Asian          18              0.81 (0.70, 0.94)      0.006                                          0.995                                                  0.016[^3^](#T4TFN3){ref-type="table-fn"}   0.048[^3^](#T4TFN3){ref-type="table-fn"}   0.355[^3^](#T4TFN3){ref-type="table-fn"}   0.847                                      0.982
                               SLE            10              0.74 (0.61, 0.89)      0.001                                          0.866                                                  0.005[^3^](#T4TFN3){ref-type="table-fn"}   0.014[^3^](#T4TFN3){ref-type="table-fn"}   0.137[^3^](#T4TFN3){ref-type="table-fn"}   0.615                                      0.941
                               HT             2               2.05 (1.19, 3.54)      0.010                                          0.131                                                  0.186[^3^](#T4TFN3){ref-type="table-fn"}   0.407[^3^](#T4TFN3){ref-type="table-fn"}   0.883                                      0.987                                      0.999
  FAS −670 A/G GG vs. GA                                                                                                                                                                                                                                                                                                                                               
                               Overall        52              1.079 (1.004, 1.160)   0.040                                          1.000                                                  0.106[^3^](#T4TFN3){ref-type="table-fn"}   0.262[^3^](#T4TFN3){ref-type="table-fn"}   0.796                                      0.975                                      0.997
                               Caucasian      27              1.12 (1.03, 1.23)      0.018                                          1.000                                                  0.051[^3^](#T4TFN3){ref-type="table-fn"}   0.138[^3^](#T4TFN3){ref-type="table-fn"}   0.637                                      0.947                                      0.994
                               SSc            4               1.20 (1.07, 1.36)      0.004                                          1.000                                                  0.013[^3^](#T4TFN3){ref-type="table-fn"}   0.037[^3^](#T4TFN3){ref-type="table-fn"}   0.299[^3^](#T4TFN3){ref-type="table-fn"}   0.811                                      0.977
  FAS −670 A/G GG+GA vs. AA                                                                                                                                                                                                                                                                                                                                            
                               Asian          18              0.83 (0.74, 0.92)      \<0.001                                        1.000                                                  0.001[^3^](#T4TFN3){ref-type="table-fn"}   0.003[^3^](#T4TFN3){ref-type="table-fn"}   0.037[^3^](#T4TFN3){ref-type="table-fn"}   0.280[^3^](#T4TFN3){ref-type="table-fn"}   0.795
                               SLE            10              0.78 (0.67, 0.90)      \<0.001                                        0.984                                                  0.002[^3^](#T4TFN3){ref-type="table-fn"}   0.006[^3^](#T4TFN3){ref-type="table-fn"}   0.063[^3^](#T4TFN3){ref-type="table-fn"}   0.403[^3^](#T4TFN3){ref-type="table-fn"}   0.871
                               MS             6               0.83 (0.70, 0.99)      0.038                                          0.993                                                  0.104[^3^](#T4TFN3){ref-type="table-fn"}   0.258[^3^](#T4TFN3){ref-type="table-fn"}   0.792                                      0.975                                      0.997
                               HT             2               1.58 (1.03, 2.42)      0.035                                          0.406                                                  0.208[^3^](#T4TFN3){ref-type="table-fn"}   0.440[^3^](#T4TFN3){ref-type="table-fn"}   0.896                                      0.989                                      0.999
  FAS −670 A/G GG vs. GA+AA                                                                                                                                                                                                                                                                                                                                            
                               Caucasian      27              1.10 (1.01, 1.19)      0.018                                          1.000                                                  0.050[^3^](#T4TFN3){ref-type="table-fn"}   0.136[^3^](#T4TFN3){ref-type="table-fn"}   0.634                                      0.946                                      0.994
                               SSc            4               1.14 (1.02, 1.28)      0.027                                          1.000                                                  0.074[^3^](#T4TFN3){ref-type="table-fn"}   0.193[^3^](#T4TFN3){ref-type="table-fn"}   0.725                                      0.964                                      0.996
                               HT             2               1.68 (1.06, 2.68)      0.029                                          0.317                                                  0.218[^3^](#T4TFN3){ref-type="table-fn"}   0.455[^3^](#T4TFN3){ref-type="table-fn"}   0.902                                      0.989                                      0.999
  FAS −1377 G/A A vs. G                                                                                                                                                                                                                                                                                                                                                
                               Overall        15              1.11 (1.03, 1.20)      0.009                                          1.000                                                  0.025[^3^](#T4TFN3){ref-type="table-fn"}   0.073[^3^](#T4TFN3){ref-type="table-fn"}   0.464[^3^](#T4TFN3){ref-type="table-fn"}   0.897                                      0.989
                               Asian          8               1.15 (1.05, 1.25)      0.001                                          1.000                                                  0.003[^3^](#T4TFN3){ref-type="table-fn"}   0.009[^3^](#T4TFN3){ref-type="table-fn"}   0.092[^3^](#T4TFN3){ref-type="table-fn"}   0.504                                      0.911
                               High quality   10              1.14 (1.05, 1.24)      0.002                                          1.000                                                  0.007[^3^](#T4TFN3){ref-type="table-fn"}   0.020[^3^](#T4TFN3){ref-type="table-fn"}   0.183[^3^](#T4TFN3){ref-type="table-fn"}   0.693                                      0.958
  FAS −1377 G/A AA vs. GG                                                                                                                                                                                                                                                                                                                                              
                               Overall        15              1.23 (1.03, 1.47)      0.023                                          0.985                                                  0.065[^3^](#T4TFN3){ref-type="table-fn"}   0.173[^3^](#T4TFN3){ref-type="table-fn"}   0.696                                      0.959                                      0.996
                               Asian          8               1.27 (1.04, 1.54)      0.015                                          0.955                                                  0.045[^3^](#T4TFN3){ref-type="table-fn"}   0.125[^3^](#T4TFN3){ref-type="table-fn"}   0.610                                      0.940                                      0.994
                               High quality   10              1.31 (1.08, 1.59)      0.007                                          0.915                                                  0.020[^3^](#T4TFN3){ref-type="table-fn"}   0.058[^3^](#T4TFN3){ref-type="table-fn"}   0.405[^3^](#T4TFN3){ref-type="table-fn"}   0.873                                      0.986
  FAS −1377 G/A AA+AG vs. GG                                                                                                                                                                                                                                                                                                                                           
                               Overall        15              1.14 (1.02, 1.26)      0.010                                          1.000                                                  0.030[^3^](#T4TFN3){ref-type="table-fn"}   0.085[^3^](#T4TFN3){ref-type="table-fn"}   0.505                                      0.911                                      0.990
                               Asian          8               1.21 (1.07, 1.36)      0.001                                          1.000                                                  0.004[^3^](#T4TFN3){ref-type="table-fn"}   0.012[^3^](#T4TFN3){ref-type="table-fn"}   0.121[^3^](#T4TFN3){ref-type="table-fn"}   0.581                                      0.933
                               High quality   10              1.17 (1.05, 1.31)      0.005                                          1.000                                                  0.019[^3^](#T4TFN3){ref-type="table-fn"}   0.055[^3^](#T4TFN3){ref-type="table-fn"}   0.391[^3^](#T4TFN3){ref-type="table-fn"}   0.866                                      0.985

Chi-square test was used to calculate the genotype frequency distributions.

Statistical power was calculated using the number of observations in the subgroup and the OR and *P*-values in this table.

The level of FPRP threshold was set at 0.5 and noteworthy findings are presented.

TSA results {#sec3-8}
-----------

In the TSA of association of *FAS* −670 A/G polymorphism and autoimmune diseases risk, the cumulative Z-curve neither crossed conventional boundary nor trial sequential monitoring boundary, however, the sample size reached RIS (3365) in allelic model ([Figure 2](#F2){ref-type="fig"}A). In the TSA of association of *FAS* −1377 G/A polymorphism and autoimmune diseases risk, the sample size also reached RIS (4387) and the cumulative Z-curve crossed the conventional boundary, although the cumulative Z-curve did not cross trial sequential monitoring boundary in allelic model ([Figure 2](#F2){ref-type="fig"}B). The TSA results indicated that the cumulative evidence was reliable and sufficient, and no additional studies were required.

![Trial sequential analyses of the associations between *FAS* polymorphisms and autoimmune diseases risk\
The RIS was calculated based on a type I error = 5%, power = 80%, and RRR = 20%. (**A**) *FAS* −670 A/G polymorphism; (**B**) *FAS* −1377G/A polymorphism.](bsr-40-bsr20191197-g2){#F2}

Discussion {#sec4}
==========

Our results showed that ethnicity, disease type, and quality score may be the factors of heterogeneity across all studies of association between *FAS* −670 A/G polymorphism and autoimmune diseases, and quality score may be the factor of heterogeneity across all studies of association between *FAS* −1377 G/A polymorphism and autoimmune diseases. In the ethnicity stratification analysis, the results of our meta-analysis revealed diverse associations between the *FAS* −670 A/G and −1377 G/A polymorphisms and various autoimmune diseases in different ethnic groups. The findings indicated that the *FAS* gene polymorphisms might play different roles in different ethnic groups. This suggests that ethnic differences may be involved in the genetic backgrounds of these patients. There are several possible explanations for such an ethnic discrepancy. First, different populations usually have different patterns of linkage disequilibrium. The *FAS* −670 A/G and −1377 G/A polymorphisms may be in close linkage with different nearby causal variants in different populations. Second, the *FAS* −670 A/G and −1377 G/A polymorphisms may interact with environmental and genetic factors or combined effects among different ethnicities. Furthermore, lifestyle factors such as alcohol consumption, cigarette smoking, nutritional status, and menopausal status may also explain this discrepancy. Finally, study numbers and sample sizes were relatively small in the stratification analysis by ethnicity, which may have resulted in inadequate statistical power to detect associations between the *FAS* −670 A/G and −1377 G/A polymorphisms and autoimmune diseases.

In the disease-type stratification analysis, the *FAS* −670 G allele was associated with an increased risk of SSc and HT and with a decreased risk of SLE, MS, and AIH (in Asians) but was not associated with other autoimmune diseases. These findings may reflect differences in the risks of various autoimmune diseases due to differences in environmental and genetic backgrounds. The present results indicate that the *FAS* −670 G allele is associated with a decreased risk of SLE, MS, and AIH (in Asians), which conflicts with a previous finding that the *FAS* −670 G allele in the *FAS* promoter was associated with an increased risk of autoimmune diseases \[[@B22],[@B78]\]. One possible mechanism by which this allele may reduce the risk of SLE, MS, and AIH (in Asians) is by a reduction in soluble FAS (sFAS). The FAS protein exists in two isoforms, one a transmembrane protein and the other a soluble protein. sFAS expression is highly regulated at the mRNA transcript level \[[@B79],[@B80]\]. Transcription of both FAS and sFAS is driven by the same gene promoter \[[@B22]\], with alternative splicing of the *FAS* mRNA resulting in a variant that lacks exon 6, which encodes the transmembrane domain of FAS \[[@B81]\]. Plasma sFAS, an antiapoptotic molecule, has been found to block apoptosis in autoreactive lymphocytes by competing with FAS for FASL or soluble FASL binding in SLE, MS, and AIH (in Asians) \[[@B79],[@B82]\]. Similarly, this may explain why the *FAS* −670 G allele was associated with an increased risk of autoimmune diseases in Caucasians and with a decreased risk in Asians. For *FAS* −1377 G/A polymorphism, subgroup analysis was not performed owing to the limited study number. The *FAS* −1377 G/A polymorphism occurs at the consensus sequence of transcription factor SP1 binding site in the silencer region \[[@B48]\]. The *FAS* −1377 A allele may destroy SP1 transcription factor binding sites, resulting in reduced promoter activity and FAS expression \[[@B18]\]. Abnormal apoptosis mediated by the FASL interaction with the FAS receptor is involved in the pathogenesis of several autoimmune diseases \[[@B19]\].

We performed a meta-analysis of data from patients diagnosed with autoimmune diseases (SLE, MS, RA, AIH, LN, SSc, AA, pSS, HT, GBS, PBC, vitiligo, GD, T1D, IAA, JIA, and SPA) and healthy controls. This meta-analysis differs from the seven previous meta-analyses \[[@B43],[@B61]\] because the present study included 33 more studies (consisting of new studies with same and different disease types) \[[@B15],[@B17],[@B22],[@B27],[@B32],[@B37],[@B41],[@B43],[@B50],[@B52],[@B59],[@B60]\] and yielded several novel and distinct findings. One previous meta-analysis \[[@B62]\] including SLE, RA, SSc, pSS, JIA, and SPA demonstrated that the *FAS* −670 A/G polymorphism might be associated with the risk of rheumatic disease, especially in Asians, SLE and RA, and the *FAS* −1377 G/A polymorphism was associated with SLE risk. Compared with this meta-analysis, our meta-analysis focused on overall autoimmune diseases risk and showed that *FAS* −670 A/G polymorphism was associated with autoimmune diseases risk in Caucasians, MS, SSc and HT; and the *FAS* −1377 G/A polymorphism was associated with autoimmune diseases risk in Asians and high quality studies, which were different from the previous meta-analyses. One meta-analysis \[[@B43]\] showed that the *FAS* −670 A/G polymorphism may be associated with SLE risk in the Chinese population. Two meta-analyses \[[@B64],[@B66]\] suggested that the *FAS* −670 A/G and −1377 G/A polymorphisms was associated with the risk of SLE, stratification by ethnicity indicated an association between the *FAS* −670 A/G and SLE in Asian populations. Two meta-analyses \[[@B61],[@B63]\] showed that the *FAS* −670 A/G polymorphism was not associated with the risk of RA. One meta-analysis \[[@B65]\] suggested that the *FAS* −670 A/G polymorphism was not associated with the risk of AIH. These six meta-analyses focused on the association between *FAS* polymorphism and a single disease (SLE, RA, or AIH). Compared with these meta-analyses, our meta-analysis covered overall autoimmune diseases, and subgroup analyses were performed by ethnicity, disease type, and quality score, thereby yielding several novel and distinct findings. Furthermore, some previous meta-analyses \[[@B63],[@B65]\] including several studies \[[@B25],[@B30],[@B31],[@B40]\] made some errors when extracting the data. Thus, we here added 33 new studies \[[@B15],[@B17],[@B22],[@B27],[@B32],[@B37],[@B41],[@B43],[@B50],[@B52],[@B59],[@B60]\] on SLE, MS, pSS, AA, PBC, HT, GBS, LN, vitiligo, T1D, IAA, and GD and corrected the previous errors, providing more reliable results. In addition, FPRP test was performed to support that the evidence of our results was robust and sufficiently conclusive, and the result of TSA showed that there was sufficient evidence and much larger sample size to support these conclusions, thereby increasing the statistical power. We strongly believe that our findings can help resolve many of the controversies of the association of *FAS* polymorphism and autoimmune diseases.

Sensitivity analysis are generally performed to assess the robustness of meta-analyses by excluding and including HWE-deviating studies from genetic association studies, which is a recommended approach \[[@B86]\]. Probable explanations for deviation from HWE include nonrandom mating, population stratification, selection bias, genotyping error, inbreeding, genetic drift, chance, differential survival of marker carriers, or combinations of these reasons \[[@B87]\]. However, key empirical evidence does not support a strong association between estimates of genetic effect and deviations from HWE \[[@B88]\]. Nonetheless, the findings of our meta-analysis should be interpreted with caution in the case of material alterations in results after excluding the HWE-deviating studies.

The present study has several limitations that should be considered when interpreting the conclusions. First, only case--control studies were considered for inclusion. Selection bias and unmeasured confounding can occur at both the design and analysis stages of observational studies. Second, this analysis only included articles published in English and Chinese; this may reduce the credibility of the results because of language bias \[[@B89]\]. Third, our study only analyzed a single locus, single nucleotide polymorphism (SNP) −670 A/G and −1377 G/A in the *FAS* gene and did not investigate associations between genetic haplotypes containing the *FAS* −670 A/G and −1377 G/A polymorphisms and the risk of autoimmune diseases because of inadequate haplotype data. It is unknown whether other genetic mutations contribute to changes in the expression or function of the *FAS* gene. For uncovering the genetic causes of disease, haplotypes provide more information and have a greater influence than genotypes and single SNPs. Fourth, most studies included in our analysis were performed in the Caucasian and Asian populations; therefore, our results may apply only to these ethnic groups. Additional studies of other ethnicities are needed. Fifth, autoimmune diseases are multifactorial diseases caused by interactions between genetic and environmental factors, meaning that the *FAS* −670 A/G and −1377 G/A polymorphisms may only partially influence the pathogenesis of autoimmune diseases; this may lead to bias in the present results. Finally, the findings of our meta-analysis should be interpreted with caution in the case of heterogeneity observed under some genetic models.

Translating information of genetic associations into clinical diagnostics would help with improved understanding of the autoimmune diseases' etiology. Establishing evidence-based medical evidence of genetic susceptibility to autoimmune diseases risk might facilitate the preventive and therapeutic strategies, which has a beneficial clinical utility for not only clinicians and researchers but also patients.

In summary, our meta-analysis suggested that the *FAS* −670 A/G polymorphism might be associated with the risk of autoimmune diseases, especially in Caucasians and Asians, SLE, MS, SSc, and HT. Moreover, the *FAS* −670 A/G polymorphism might be associated with the risk of autoimmune diseases in Asian patients with SLE or AIH and Caucasian patients with SLE, MS, or SSc. The *FAS* −1377 G/A/ polymorphism might be associated with the risk of autoimmune diseases, specifically for Asians and high quality studies. Stratification analysis showed that ethnicity, disease type and quality score might be the factors of heterogeneity across all studies of association between *FAS* −670 A/G polymorphism and autoimmune diseases risk, and quality score might be the factor of heterogeneity across all studies of association between *FAS* −1377 G/A polymorphism and autoimmune diseases risk.
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AA

:   alopecia areata

AIH

:   autoimmune hepatitis

CI

:   confidence interval

FASL

:   FAS-ligand

FPRP

:   false-positive report probability

GBS

:   Guillain--Barré syndrome

GD

:   Graves' disease

HT

:   Hashimoto's thyroiditis

HWE

:   Hardy--Weinberg equilibrium

IAA

:   idiopathic aplastic anemia

JIA

:   juvenile idiopathic arthritis

LN

:   lupus nephritis

MS

:   multiple sclerosis

NOS

:   Newcastle--Ottawa scale

OR

:   odds ratio

PBC

:   primary biliary cirrhosis

pSS

:   primary Sjögren's syndrome

RA

:   rheumatoid arthritis

RIS

:   required information size

sFAS

:   soluble FAS

SLE

:   systemic lupus erythematosus

SNP

:   single nucleotide polymorphism

SPA

:   spondyloarthropathy

SP1

:   stimulatory protein 1

SSc

:   systemic sclerosis

TNF

:   tumor necrosis factor

TSA

:   trial sequential analysis

T1D

:   type 1 diabetes mellitus
